15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Aclaris Therapeutics Inc, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $10.00 to $16.00, a moderate spread. The average target of $11.71 sits 93% above the current $6.05. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 7 over recent months. On the fundamentals, the Street sees revenue growth near -27% this year and -6% next, consensus EPS building from about $-0.17 next quarter toward $-0.79 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Strong Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Aclaris Therapeutics Inc.
As of Sep, 7 of 7 firms rate ACRS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ACRS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.25 – $-0.13 · 10 analysts · +9% YoY
Next period, 10 analysts expect Aclaris Therapeutics Inc to earn $-0.17 a share (range $-0.25 – $-0.13), versus $-0.16 a year earlier. Full-year consensus is $-0.64, growing to $-0.79 the year after.
REVENUE · NEXT QUARTER
$1.4M
Range $0 – $2.7M · 10 analysts · -59% YoY
Revenue is expected to reach $1.4M (range $0 – $2.7M), -59.0% year-over-year. Full-year consensus is $6.3M, rising to $5.3M next year.
Top analysts covering Aclaris Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACRS.
#1
Roger Song
Jefferies · Rank #101
Buy
$7.00+15.6% to target
Overall win rate
43%
+ Follow
#2
Jeff Jones
Oppenheimer · Rank #247
Buy
$10.00+65.2% to target
Overall win rate
31%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #312
Buy
$16.00+164.2% to target
Overall win rate
36%
+ Follow
#4
MF
Martin Fan
Wedbush
Buy
$10.00+65.2% to target
Coverage
—
+ Follow
#5
Louise Chen
Scotiabank
Buy
$9.00+48.6% to target
Coverage
—
+ Follow
ACRS stock forecast FAQ
What is ACRS's average 12-month price target?+
The 6 analysts with a live target average $11.71 for Aclaris Therapeutics Inc over the next 12 months, ranging from a $16.00 high to a $10.00 low.
Is ACRS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ACRS?+
The Street-high target is $16.00 (HC Wainwright & Co.), and the Street-low is $10.00 (Canaccord Genuity). The average of all 6 active targets is $11.71.
How many Wall Street analysts cover ACRS?+
7 analysts have an active rating on Aclaris Therapeutics Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering ACRS?+
Among analysts who currently cover ACRS, Roger Song of Jefferies has the strongest overall Quantellect track record (Rank #101). Their current call is Buy with a $7.00 target.
What is Aclaris Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.25 – $-0.13) across 10 analysts. Full-year EPS is projected at $-0.64, rising to $-0.79 the following year.
How much revenue is Aclaris Therapeutics Inc expected to report next quarter?+
Consensus revenue is $1.4M (range $0 – $2.7M). Full-year revenue is projected at $6.3M, growing to $5.3M next year.
Have analysts been upgrading or downgrading ACRS lately?+
As of Sep, 7 of 7 firms rate ACRS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACRS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
